Being aware of potentially fatal interstitial lung disease in patients with head and neck cancer treated with concurrent cetuximab and radiotherapy
Mari Shimada, Hiroshi Nishino, Toru Sasaki and 2 more
Cogent Medicine · 2017
doi:10.1080/2331205x.2017.1284419 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Cetuximab-induced interstitial lung disease (ILD), especially for tumors in the head and neck area, has rarely been reported. The present case may serve as an important reference to alert clinicians who use this chemotherapeutic agent. We report a case of acute ILD in a 66-year-old male with double cancers (oral floor cancer T4aN0M0 and supraglottic cancer T2N0M0), who received concurrent cetuximab and radiation therapy. He had severe dyspnea on day 51 along with worsened bilateral, progressive infiltration in chest X-ray, elevated C-reactive protein, Krebs von den Lungen 6 (KL-6), Surfactant Protein D (SP-D) and Surfactant Protein A (SP-A), and was diagnosed with ILD. He was treated with High-dose methylprednisone (1 mg/kg) soon after the diagnosis was made. He recovered remarkably and was discharged at day 100. For early detection of ILD, we suggest weekly chest X-rays for cetuximab-treated patients. In suspicious cases, High-resolution computed tomography scan and measurements of KL-6, SP-A, and SP-D levels should be considered.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.